Pharma manufacturing 'boom' faces high costs, potential delays. Anjalee Khemlani. June 15, 2025 at 10:00 AM. Copied; With more than $270 billion in commitments to date, a new wave of ...

Tariffs on pharma imports, as a measure to encourage nearshored manufacturing, are more than offset by the costs of relocation for drug companies, as per Mina Tadrous, assistant professor of drug ...

US drugmakers' shares drop 3% to 6% premarket European, Indian healthcare stocks drag down broader indexes Trump aims to shift pharma manufacturing to US, but analysts doubtful April 9 (Reuters ...

New Delhi [India], April 11 (ANI): Siddharth Mittal, CEO and Managing Director of Biocon Limited, on Friday questioned who would pay the price to shift their establishments to the US where pharma ...

Sources do not expect Trump to announce pharma-specific tariffs Wednesday; Trump may announce plans to launch a study for pharma tariffs; New U.S. pharma manufacturing could take years to build ...

eligible patients, pharma& committed to investing in bio-manufacturing capabilities at. pharma&’s wholly owned manufacturing plant subsidiary, Loba biotech GmbH. This significant. investment was ...

The pharma giant said the investment would create more than 12,000 jobs, as it joins rival Novartis in expanding its footprint in the country amid President Trump’s tariff threats.

For the pharma industry, the question becomes: How can we properly prepare for reshoring while ensuring we're building tomorrow's manufacturing infrastructure today?